The following is a listing of myeloma treatments associated with this tag.
View all treatments in development for myeloma patients around the US.
Belantamab Mafodotin
Belantamab Mafodotin (formerly GSK2857916) is an antibody-drug conjugate (ADC) directed against the B-cell maturation antigen (BCMA).
CLR 131
CLR 131 is a phospholipid drug conjugate (PDC) that selectively delivers radiation (a cytotoxic radioisotope called iodine-131) directly to malignant cancer cells. The US Food and Drug Administration (FDA) has granted Cellectar an orphan drug designation for CLR 131.
Melphalan Flufenamide (Melflufen)
Melflufen is a peptide-conjugated alkylator (a new type of cancer therapy) that rapidly delivers a toxic drug payload into myeloma cells, resulting in myeloma cell death.
TNB-383B
TNB-383B is a bi-specific antibody, meaning that it interacts with two molecules in your body. One molecule is called B-Cell Maturation Antigen (BMCA) and is found on your multiple myeloma cells. The second is called CD3 and is present on your killer T-cells.
SparkCures Verified Accurate, up-to-date information. Learn more
The following is a listing of treatments in development for patients with multiple myeloma who have received one to two prior lines of therapy.
Belantamab Mafodotin
Belantamab Mafodotin (formerly GSK2857916) is an antibody-drug conjugate (ADC) directed against the B-cell maturation antigen (BCMA).
CLR 131
CLR 131 is a phospholipid drug conjugate (PDC) that selectively delivers radiation (a cytotoxic radioisotope called iodine-131) directly to malignant cancer cells. The US Food and Drug Administration (FDA) has granted Cellectar an orphan drug designation for CLR 131.
Melphalan Flufenamide (Melflufen)
Melflufen is a peptide-conjugated alkylator (a new type of cancer therapy) that rapidly delivers a toxic drug payload into myeloma cells, resulting in myeloma cell death.
TNB-383B
TNB-383B is a bi-specific antibody, meaning that it interacts with two molecules in your body. One molecule is called B-Cell Maturation Antigen (BMCA) and is found on your multiple myeloma cells. The second is called CD3 and is present on your killer T-cells.
SparkCures Verified Accurate, up-to-date information. Learn more
The following is a listing of treatments in development for patients with multiple myeloma who have received three or more prior lines of therapy.
Belantamab Mafodotin
Belantamab Mafodotin (formerly GSK2857916) is an antibody-drug conjugate (ADC) directed against the B-cell maturation antigen (BCMA).
CLR 131
CLR 131 is a phospholipid drug conjugate (PDC) that selectively delivers radiation (a cytotoxic radioisotope called iodine-131) directly to malignant cancer cells. The US Food and Drug Administration (FDA) has granted Cellectar an orphan drug designation for CLR 131.
Melphalan Flufenamide (Melflufen)
Melflufen is a peptide-conjugated alkylator (a new type of cancer therapy) that rapidly delivers a toxic drug payload into myeloma cells, resulting in myeloma cell death.
TNB-383B
TNB-383B is a bi-specific antibody, meaning that it interacts with two molecules in your body. One molecule is called B-Cell Maturation Antigen (BMCA) and is found on your multiple myeloma cells. The second is called CD3 and is present on your killer T-cells.
SparkCures Verified Accurate, up-to-date information. Learn more
The following is a listing of myeloma clinical trials associated with this tag.
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.